CN103796644B - 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 - Google Patents

芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 Download PDF

Info

Publication number: CN103796644B
Authority: CN; China
Prior art keywords: compound; fluoro; methylene; bisbenzonitrile; dose
Prior art date: 2011-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201280043378.9A

Other languages

English (en)

Chinese (zh)

Other versions

CN103796644A (zh

Inventor

A·泰勒

L·B·克里克斯坦

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-08

Filing date

2012-09-06

Publication date

2017-05-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103796644(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-09-06 Application filed by Novartis AG filed Critical Novartis AG

2014-05-14 Publication of CN103796644A publication Critical patent/CN103796644A/zh

2017-05-03 Application granted granted Critical

2017-05-03 Publication of CN103796644B publication Critical patent/CN103796644B/zh

Status Active legal-status Critical Current

2032-09-06 Anticipated expiration legal-status Critical

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Inorganic Chemistry (AREA)
Gynecology & Obstetrics (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN201280043378.9A 2011-09-08 2012-09-06 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 Active CN103796644B (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161532459P	2011-09-08	2011-09-08
US61/532,459		2011-09-08
US201261638588P	2012-04-26	2012-04-26
US61/638,588		2012-04-26
PCT/US2012/053844 WO2013036562A1 (en)	2011-09-08	2012-09-06	Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Publications (2)

Publication Number	Publication Date
CN103796644A CN103796644A (zh)	2014-05-14
CN103796644B true CN103796644B (zh)	2017-05-03

Family

ID=46846026

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201280043378.9A Active CN103796644B (zh)	2011-09-08	2012-09-06	芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途
CN201280043614.7A Active CN103781476B (zh)	2011-09-08	2012-09-06	包含芳香酶抑制剂的药物组合物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN201280043614.7A Active CN103781476B (zh)	2011-09-08	2012-09-06	包含芳香酶抑制剂的药物组合物

Country Status (31)

Country	Link
US (4)	US9295668B2 (2)
EP (2)	EP2753312B1 (2)
JP (2)	JP6051467B2 (2)
KR (3)	KR101872561B1 (2)
CN (2)	CN103796644B (2)
AR (1)	AR087790A1 (2)
AU (2)	AU2012304694B2 (2)
BR (2)	BR112014005434B1 (2)
CA (2)	CA2846884C (2)
CL (1)	CL2014000552A1 (2)
CY (2)	CY1118461T1 (2)
DK (2)	DK2753313T3 (2)
ES (2)	ES2613666T3 (2)
HR (2)	HRP20170003T1 (2)
HU (2)	HUE031478T2 (2)
IL (1)	IL231234A (2)
IN (1)	IN2014DN01619A (2)
LT (2)	LT2753313T (2)
MX (2)	MX360315B (2)
PE (1)	PE20141584A1 (2)
PH (1)	PH12014500435A1 (2)
PL (2)	PL2753312T3 (2)
PT (2)	PT2753312T (2)
RU (2)	RU2617510C2 (2)
SG (2)	SG10201607503WA (2)
SI (2)	SI2753312T1 (2)
TN (1)	TN2014000059A1 (2)
TW (1)	TW201316987A (2)
UY (1)	UY34315A (2)
WO (2)	WO2013036562A1 (2)
ZA (1)	ZA201401040B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2753312T (pt) *	2011-09-08	2017-02-03	Mereo Biopharma 2 Ltd	Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas
US10324099B2 (en) *	2014-03-26	2019-06-18	The Regents Of The University Of California	Ultrasensitive androgen receptor bioassay
PE20170201A1 (es) *	2014-07-07	2017-04-08	Novartis Ag	Formas de dosificacion farmaceutica
GB201614179D0 (en) *	2016-08-19	2016-10-05	Mereo Biopharma 2 Ltd	Dosage regimen for the treatment of endometriosis
EP3592338A1 (en) *	2017-03-08	2020-01-15	ARIAD Pharmaceuticals, Inc.	Pharmaceutical formulations comprising 5-chloro-n4
CA3078652A1 (en)	2017-10-12	2019-04-18	Novo Nordisk A/S	Semaglutide in medical therapy
USD894149S1 (en) *	2018-08-16	2020-08-25	Alibaba Group Holding Limited	Information terminal for payment
USD894148S1 (en) *	2018-08-16	2020-08-25	Alibaba Group Holding Limited	Information terminal for payment
JP7121999B2 (ja) *	2019-09-26	2022-08-19	学校法人九州文化学園	男性性腺機能低下症治療剤
US12552754B1 (en)	2025-06-11	2026-02-17	ReproNovo SA	Leflutrozole compositions of matter and processes for preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996009057A1 (de) *	1994-09-22	1996-03-28	Schering Aktiengesellschaft	Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann
US5637605A (en) *	1990-12-12	1997-06-10	Ciba Geigy Corporation	α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
CN1281361A (zh) *	1997-12-12	2001-01-24	霍莫斯医疗有限公司	芳香酶抑制剂治疗泌尿疾病的用途和研究泌尿疾病的方法
WO2002002113A1 (en) *	2000-07-05	2002-01-10	Astrazeneca Ab	Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
WO2003082254A1 (en) *	2002-04-03	2003-10-09	Jencap Research Ltd.	Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
CN1549734A (zh) *	2001-04-17	2004-11-24	��˹ó�׹ɷ��޹�˾	增强辅助生殖的芳香酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4749713A (en) *	1986-03-07	1988-06-07	Ciba-Geigy Corporation	Alpha-heterocycle substituted tolunitriles
US7101573B2 (en)	2001-09-28	2006-09-05	Mcneil-Pcc, Inc.	Simethicone solid oral dosage form
EP1937251A2 (en)	2005-04-25	2008-07-02	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
WO2009066712A1 (ja) *	2007-11-21	2009-05-28	Kracie Pharma, Ltd.	アロマターゼ阻害剤
PT2753312T (pt) *	2011-09-08	2017-02-03	Mereo Biopharma 2 Ltd	Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas

2012
- 2012-09-06 PT PT127589653T patent/PT2753312T/pt unknown
- 2012-09-06 SG SG10201607503WA patent/SG10201607503WA/en unknown
- 2012-09-06 MX MX2014002780A patent/MX360315B/es active IP Right Grant
- 2012-09-06 ES ES12758965.3T patent/ES2613666T3/es active Active
- 2012-09-06 US US14/342,810 patent/US9295668B2/en active Active
- 2012-09-06 HR HRP20170003TT patent/HRP20170003T1/hr unknown
- 2012-09-06 EP EP12758965.3A patent/EP2753312B1/en active Active
- 2012-09-06 AU AU2012304694A patent/AU2012304694B2/en active Active
- 2012-09-06 LT LTEP12758966.1T patent/LT2753313T/lt unknown
- 2012-09-06 DK DK12758966.1T patent/DK2753313T3/en active
- 2012-09-06 JP JP2014529833A patent/JP6051467B2/ja active Active
- 2012-09-06 KR KR1020147006171A patent/KR101872561B1/ko active Active
- 2012-09-06 IN IN1619DEN2014 patent/IN2014DN01619A/en unknown
- 2012-09-06 HU HUE12758965A patent/HUE031478T2/hu unknown
- 2012-09-06 HR HRP20170002TT patent/HRP20170002T1/hr unknown
- 2012-09-06 PL PL12758965T patent/PL2753312T3/pl unknown
- 2012-09-06 PE PE2014000325A patent/PE20141584A1/es not_active Application Discontinuation
- 2012-09-06 RU RU2014113575A patent/RU2617510C2/ru active
- 2012-09-06 PL PL12758966T patent/PL2753313T3/pl unknown
- 2012-09-06 HU HUE12758966A patent/HUE031435T2/en unknown
- 2012-09-06 AU AU2012304693A patent/AU2012304693B2/en active Active
- 2012-09-06 SI SI201230850T patent/SI2753312T1/sl unknown
- 2012-09-06 DK DK12758965.3T patent/DK2753312T3/da active
- 2012-09-06 CA CA2846884A patent/CA2846884C/en active Active
- 2012-09-06 SG SG2014012132A patent/SG2014012132A/en unknown
- 2012-09-06 US US14/342,813 patent/US9370505B2/en active Active
- 2012-09-06 SI SI201230848A patent/SI2753313T1/sl unknown
- 2012-09-06 JP JP2014529832A patent/JP6280501B2/ja active Active
- 2012-09-06 EP EP12758966.1A patent/EP2753313B1/en active Active
- 2012-09-06 KR KR1020147006170A patent/KR20140071358A/ko not_active Ceased
- 2012-09-06 WO PCT/US2012/053844 patent/WO2013036562A1/en not_active Ceased
- 2012-09-06 CN CN201280043378.9A patent/CN103796644B/zh active Active
- 2012-09-06 BR BR112014005434-7A patent/BR112014005434B1/pt active IP Right Grant
- 2012-09-06 MX MX2014002773A patent/MX343902B/es active IP Right Grant
- 2012-09-06 CA CA2845929A patent/CA2845929C/en active Active
- 2012-09-06 KR KR1020187007058A patent/KR20180030254A/ko not_active Ceased
- 2012-09-06 BR BR112014004879A patent/BR112014004879B1/pt active IP Right Grant
- 2012-09-06 PH PH1/2014/500435A patent/PH12014500435A1/en unknown
- 2012-09-06 RU RU2014113334A patent/RU2628808C2/ru active
- 2012-09-06 AR ARP120103283A patent/AR087790A1/es unknown
- 2012-09-06 PT PT127589661T patent/PT2753313T/pt unknown
- 2012-09-06 ES ES12758966.1T patent/ES2613667T3/es active Active
- 2012-09-06 CN CN201280043614.7A patent/CN103781476B/zh active Active
- 2012-09-06 WO PCT/US2012/053846 patent/WO2013036563A1/en not_active Ceased
- 2012-09-06 LT LTEP12758965.3T patent/LT2753312T/lt unknown
- 2012-09-07 TW TW101132840A patent/TW201316987A/zh unknown
- 2012-09-10 UY UY0001034315A patent/UY34315A/es not_active Application Discontinuation
2014
- 2014-02-10 TN TNP2014000059A patent/TN2014000059A1/en unknown
- 2014-02-11 ZA ZA2014/01040A patent/ZA201401040B/en unknown
- 2014-02-27 IL IL231234A patent/IL231234A/en active IP Right Grant
- 2014-03-07 CL CL2014000552A patent/CL2014000552A1/es unknown
2016
- 2016-02-22 US US15/050,394 patent/US9750724B2/en active Active
- 2016-05-27 US US15/167,867 patent/US10064844B2/en active Active
2017
- 2017-01-18 CY CY20171100074T patent/CY1118461T1/el unknown
- 2017-01-24 CY CY20171100100T patent/CY1118499T1/el unknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5637605A (en) *	1990-12-12	1997-06-10	Ciba Geigy Corporation	α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
WO1996009057A1 (de) *	1994-09-22	1996-03-28	Schering Aktiengesellschaft	Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann
CN1281361A (zh) *	1997-12-12	2001-01-24	霍莫斯医疗有限公司	芳香酶抑制剂治疗泌尿疾病的用途和研究泌尿疾病的方法
WO2002002113A1 (en) *	2000-07-05	2002-01-10	Astrazeneca Ab	Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
CN1549734A (zh) *	2001-04-17	2004-11-24	��˹ó�׹ɷ��޹�˾	增强辅助生殖的芳香酶抑制剂
WO2003082254A1 (en) *	2002-04-03	2003-10-09	Jencap Research Ltd.	Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates;Gunapala Shetty etal.;《J. Steroid Biochem. Molec. Biol.》;19971231;第61卷(第3-6期);第157-166页 *
Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata);Gunapala Shetty et al.;《Steroids》;19980831;第63卷;第414–420页，尤其摘要，第415页右栏第5段，第416页图1 *
Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism;H. de Boer et al.;《Diabetes, Obesity and Metabolism》;20051231;第7卷;第211-215页，尤其摘要，第212页右栏第3-4段 *
STRUCTURE-ACTIVITY RELATIONSHIPS AND BINDING MODEL OF NOVEL AROMATASE INHIBITORS;M. LANG et al.;《J. Steroid Biochem. Molec. Biol》;19931231;第44卷(第4-6期);第421-428页，尤其摘要 *

Also Published As

Publication number	Publication date
KR20180030254A (ko)	2018-03-21
PT2753312T (pt)	2017-02-03
SG10201607503WA (en)	2016-10-28
JP2014526465A (ja)	2014-10-06
PL2753312T3 (pl)	2017-06-30
US20140213622A1 (en)	2014-07-31
LT2753313T (lt)	2017-02-10
UY34315A (es)	2013-04-30
BR112014005434A2 (pt)	2017-04-04
CA2846884C (en)	2019-04-09
US20140309267A1 (en)	2014-10-16
SI2753312T1 (sl)	2017-10-30
BR112014004879A2 (pt)	2017-03-14
TN2014000059A1 (en)	2015-07-01
CL2014000552A1 (es)	2014-09-12
HUE031478T2 (hu)	2017-07-28
US9370505B2 (en)	2016-06-21
TW201316987A (zh)	2013-05-01
JP6051467B2 (ja)	2016-12-27
EP2753312B1 (en)	2016-12-14
WO2013036562A1 (en)	2013-03-14
KR20140058619A (ko)	2014-05-14
IL231234A0 (en)	2014-04-30
MX343902B (es)	2016-11-28
MX2014002773A (es)	2014-06-05
SI2753313T1 (sl)	2017-04-26
DK2753313T3 (en)	2017-02-13
US20160346257A1 (en)	2016-12-01
RU2014113334A (ru)	2015-10-20
JP2014528932A (ja)	2014-10-30
HRP20170002T1 (hr)	2017-02-24
EP2753313B1 (en)	2016-12-14
PL2753313T3 (pl)	2017-07-31
EP2753312A1 (en)	2014-07-16
AU2012304694B2 (en)	2016-04-07
CY1118499T1 (el)	2017-07-12
BR112014004879B1 (pt)	2020-01-28
AU2012304693B2 (en)	2016-03-31
CN103781476A (zh)	2014-05-07
RU2628808C2 (ru)	2017-08-22
US9750724B2 (en)	2017-09-05
JP6280501B2 (ja)	2018-02-14
SG2014012132A (en)	2014-06-27
AU2012304694A1 (en)	2014-03-20
CY1118461T1 (el)	2017-07-12
CA2845929A1 (en)	2013-03-14
ZA201401040B (en)	2015-12-23
IN2014DN01619A (2)	2015-05-15
RU2617510C2 (ru)	2017-04-25
MX2014002780A (es)	2014-06-05
NZ621476A (en)	2016-02-26
PH12014500435A1 (en)	2019-03-22
ES2613666T3 (es)	2017-05-25
AR087790A1 (es)	2014-04-16
US10064844B2 (en)	2018-09-04
CA2845929C (en)	2018-06-19
ES2613667T3 (es)	2017-05-25
BR112014005434B1 (pt)	2021-01-05
CA2846884A1 (en)	2013-03-14
PE20141584A1 (es)	2014-11-13
DK2753312T3 (da)	2017-02-13
CN103781476B (zh)	2016-12-07
AU2012304693A1 (en)	2014-03-13
RU2014113575A (ru)	2015-10-20
CN103796644A (zh)	2014-05-14
MX360315B (es)	2018-10-29
HUE031435T2 (en)	2017-07-28
IL231234A (en)	2016-12-29
US20160243084A1 (en)	2016-08-25
US9295668B2 (en)	2016-03-29
KR20140071358A (ko)	2014-06-11
HRP20170003T1 (hr)	2017-03-10
EP2753313A1 (en)	2014-07-16
PT2753313T (pt)	2017-02-02
KR101872561B1 (ko)	2018-06-28
LT2753312T (lt)	2017-01-25
WO2013036563A1 (en)	2013-03-14

Legal Events

Date	Code	Title
2014-05-14	C06	Publication
2014-05-14	PB01	Publication
2014-09-24	C10	Entry into substantive examination
2014-09-24	SE01	Entry into force of request for substantive examination
2017-05-03	GR01	Patent grant
2017-05-03	GR01	Patent grant

Publication	Publication Date	Title
CN103796644B (zh)	2017-05-03	芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途
US20190175615A1 (en)	2019-06-13	Lipobalanced long chain testosterone esters for oral delivery
Chao et al.	2014	Male contraception
US20190240235A1 (en)	2019-08-08	Lipobalanced long chain testosterone esters for oral delivery
EP2968363B1 (en)	2020-08-19	Lipobalanced long chain testosterone esters for oral delivery
JP2006522833A (ja)	2006-10-05	エストロゲンおよびプロゲスチンの投与法
JP2019524846A (ja)	2019-09-05	子宮内膜症の治療のための投与レジメン
HK1196256A (en)	2014-12-12	Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
HK1196256B (en)	2017-09-22	Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
NZ621476B2 (en)	2016-05-27	Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases